恶性血液学领域正在通过新的免疫治疗方法转型。但治疗的心脏毒性副作用会对生活质量、治疗效果和寿命产生负面影响。目前，这些治疗所致的心脏毒性的确切机制和发病率还不清楚。这些事件被认为是由细胞因子释放综合征触发或同时发生。此外，目前没有正式的指南来提供评估、治疗和监测。我们旨在综合现有文献，并更新有关恶性血液学疾病中新疗法的心脏毒性效应，重点关注嵌合抗原受体T细胞疗法和双特异性T细胞结合剂疗法，并提出一个可能指导治疗前评估、治疗期间监测和治疗后监测的算法。

The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To date, the exact mechanism and incidence of cardiotoxicity associated with these therapies is unclear. These events are believed to be triggered or occur concurrently with cytokine release syndrome. Furthermore, there are no formal guidelines to provide evaluation, treatment, and surveillance. We aim to synthesize available literature with updates on the cardiotoxic effects of novel therapies used in malignant hematologic disorders, with a focus on chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy, along with a proposed algorithm that may guide pretreatment evaluation, monitoring during treatment, and post-treatment surveillance.